A network meta-analysis in 2023 concluded the treatment effects of SGLT2i were comparable to GLP-1 Ras and superior to TZDs and DPP-4i for the cognition outcomes related to T2DM, as measured by SUCRA [20]. Here, GCG is linked to type 2 diabetes mellitus.